Bazedoxifene: a new selective estrogen-receptor modulator for postmenopausal osteoporosis. (December 2012)

• Record Type: Journal Article
• Authors: Kung, Annie
• Is Part Of: International journal of clinical rheumatology. Volume 7:Number 6(2012)
• Page Start: 583
• Page End: 590
• Publication Date: 2012-12
• Subjects: bazedoxifene -- fracture -- osteoporosis -- SERMs; Rheumatology -- Periodicals; 616.723005
• DOI: 10.2217/ijr.12.47
• Languages: English
• ISSNs: 1758-4272

Abstract

Bazedoxifene acetate (WAY-140424; TSE-424) is an oral, nonsteroidal, indole-based selective estrogen-receptor modulator that is being clinically evaluated as a monotherapy for the prevention and treatment of osteoporosis and in combination with conjugated estrogens for the treatment of menopausal symptoms and prevention of osteoporosis. Developed by Wyeth (now Pfizer) Pharmaceuticals (NJ, USA), it is undergoing regulatory review for clinical use under the trade name Viviant™ by the US FDA. Bazedoxifene is currently marketed in Switzerland, Spain, Italy, Germany, Ireland and Japan. Its brand names in the EU and Japan are Conbriza ® and Viviant™, respectively. In the EU, Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. Bazedoxifene reduces vertebral fractures in postmenopausal osteoporotic women, and nonvertebral fractures in a subgroup of postmenopausal osteoporotic women at higher risk. This review describes the mechanism of action and summarizes the clinical experience with bazedoxifene. Current evidence indicates that bazedoxifene is effective and safe for the treatment of postmenopausal osteoporosis.